Phase 3 N=21 Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Hemophilia B
Primary: Annualized Bleeding Rate (ABR) — 2.93 bleeding episodes per year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=605 Attitudes Towards Receiving Mental Health Care Using Telehealth During the Coronavirus Disease 2019 (COVID-19) Pandemic
Psychiatric Disorder · Mental Health Disorder · Stress
Primary: Patient Choosing Telehealth as an Option for Future Care — 523; 43; 36 Participants
Phase 4 N=64 Liposomal Bupivacaine in Rotator Cuff Repair
Rotator Cuff Injury
Primary: Average Postoperative Pain Scores Over a 96 Hour Timeframe — 3.0; 3.5 score on a scale
N/A N=36 Repeated Sweet Consumption and Subsequent Sweet Food Preferences and Intake
Repeated Sweet Food Consumption
Primary: Food Preferences — 7; 1 units on a scale
N/A N=106 Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
Atrial Fibrillation · Atrial Flutter · Heart Block
Primary: Time to Achieve Hemostasis — 7; 11 Minutes
N/A N=80 Impact of PIVC Length and Gauge on Catheter Indwell Time
Indication for Peripheral Intravenous Catheterisation
Primary: Patent Indwell Time Between PIVCs of Different Length and Gauge. — 40.19; 42.96; 35.91; 36.91 hours
Phase 2 N=92 Use of Aromatherapy to Reduce Symptom Burden
Anxiety · Chemotherapy-induced Nausea and Vomiting
Primary: Chemotherapy-induced Nausea, Vomiting, and Retching (CINVR) Symptoms at Baseline, 25 Hours, and 48 Hours — 9.6; 8.5; 5.2; 4.9 score on a scale — p=0.462
Phase 3 N=1,340 Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Partial Epilepsy
Primary: Summary of Treatment-Emergent Adverse Events (TEAEs) — 76; 35; 1104; 57 participants
Phase 3 N=105 Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Menorrhagia
Primary: Number of Participants With Successful Treatment of Heavy Menstrual Bleeding — 81; 83 Participants
Phase 2 N=64 A Study of TAK-071 in People With Parkinson Disease
Parkinson Disease · Healthy Participants
Primary: Main Cohort: Change From Baseline in Stride Time (Gait) Variability During a 2-minute Dual-Task Walking Test After 6-week Treatment With TAK-071 Compared With Placebo…
Phase 2 N=172 INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
Paroxysmal Atrial Fibrillation (PAF)
Primary: Percentage of Participants With Successful Conversion of Atrial Fibrillation to Sinus Rhythm — 10; 35; 33; 41 percentage of participants
Phase 2 N=37 Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Hypertension Pulmonary Secondary · Heart Failure, Right Sided · Heart Failure With Normal Ejection Fraction
Primary: Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP) With Bicycle Exercise — -1.9; -0.5 mmHg
Phase 1 N=30 Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Cancer Of Prostate · Prostate Neoplasms · Prostate Cancer
Primary: Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy) — 36.4; 44.2; 47.1 Gray (Gy)
Phase 2 N=42 BCAA Supplementation for Concussion
Brain Concussion
Primary: Reaction Time Difference Between Drug and Placebo Groups — 2.44; 2.49; 2.52; 2.48 log(milliseconds) — p=0.871
Phase 2 N=68 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Transitional Cell Carcinoma of Bladder · Urethra Cancer · Ureter Cancer
Primary: Maximum Tolerated Dose (MTD) and/or the Recommended Dose (RD) for Dose Expansion of ALT-801 in Combination With Cisplatin and Gemcitabine or ALT-801 in Combination With…